Pemigatinib for a rare type of GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a drug called pemigatinib for people with a specific type of GIST (SDH-deficient GIST) that has spread or cannot be removed with surgery. The goal is to see if the drug can help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of SDH-deficient GIST that has spread or cannot be surgically removed.
- You must have at least one tumor that can be measured on a scan (at least 1 cm or 2 cm depending on the scan type).
- Your cancer must have gotten worse on a recent scan before joining the trial.
- You must be 18 years or older.
- You must be able to swallow and keep down pills.
- You must have adequate organ function (kidney, liver, and blood counts) as determined by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether taking imatinib before surgery can shrink or control high-risk gastrointestinal stromal tumors (GIST). If you qualify, you would receive imatinib as “neoadjuvant” (before the operation) and then move on to planned surgery.
This trial tests how well temozolomide works and how safe it is for people with GIST (a type of stomach/intestine tumor) that is SDH-deficient and has no KIT or PDGFRα mutations. It may help by targeting tumor DNA repair weakness seen in this SDH-deficient subtype.
This trial tests a new drug, olverembatinib, for GIST that lacks the SDH enzyme and has gotten worse after at least one prior treatment. It aims to see if the drug can stop or shrink the tumor.
This trial tests a new targeted therapy drug, DCC-3009, for people with advanced GIST that has a specific gene mutation (KIT or PDGFRA). It's for those who have already tried other targeted treatments and need a new option.
This Phase 2 trial tests pemigatinib, a targeted medicine, for advanced or metastatic gastrointestinal (GI) cancers that have specific FGFR1–3 gene changes. It’s for people whose cancer has grown despite prior standard treatment, and who may benefit if their tumor has the right genetic change.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
Hear when a new SDH Gene Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.